Share the QR code < / P > < p > with wechat scanning code to friends and circle of friends < / P > < p > recently, there were new sporadic cases of crown vaccine in China, and many places have started the "booster needle" vaccination of new crown vaccine. In the face of novel coronavirus pneumonia mortality rate of around 2%, the new crown treatment special drug is expected to play an important role in the development. p> < p > < / P > < p > the reporter of Beijing Daily learned on November 7 that the research and development of new crown treatment specific drugs of many Chinese pharmaceutical enterprises is progressing smoothly and will become a powerful weapon to cure critically ill patients P>
immunoglobulin clinical trials have been launched at
. Currently, China national medicine group is developing 2 new global crown treatment special drugs, new crown specific immunoglobulin and anti COVID-19 monoclonal antibody. Among them, the new crown specific immunoglobulin has obtained the approval documents for clinical trials at home and abroad issued by the State Food and Drug Administration and the Ministry of health and prevention of the UAE, and relevant clinical trials have also been carried out P>
new crown specific immunoglobulin is a specific intravenous injection of New Coronavirus with high neutralization antibody prepared from the healthy human plasma after the immunization of China's biological New Coronavirus inactivated vaccine. Because it can neutralize COVID-19, it has a good therapeutic effect on the new crown and critical patients. Novel coronavirus pneumonia, p>
, Yang Xiaoming, chairman of China biological group, said the mechanism of the drug is consistent with the plasma treatment of the new crown pneumonia rehabilitation patients. The difference is that specific immunoglobulin has higher purity, complex process and greater difficulty in research and development. Compared with convalescent patients, plasma therapy in convalescent stage is more widely used and takes effect faster. It can be used for emergency treatment of severe patients and high-risk groups Chen Kun, China's novel coronavirus pneumonia, said that the new crown specific immunoglobulin will bring new hope to the terminus of the epidemic as soon as possible and save more patients with new crown pneumonia, p>
said. Chen Kun introduced that the new crown specific immunoglobulin has been applied to patients in the recent epidemic situation in many parts of the country, and the test results are good p> < p > Drug Administration approves clinical application for combination therapy < / P > < p > recently, tengshengbo has submitted its application for emergency use authorization of new crown neutralizing antibody combination therapy brii-196 / brii-198 under development to the U.S. Food and drug administration. The application is based on the positive results of the phase 3 clinical trial supported by the National Institutes of health. The results show that this combination therapy reduces the risk of hospitalization and death by 78% compared with placebo p> < p > significant reductions in hospitalization and mortality were observed in subjects who started treatment early (within 5 days after the onset of symptoms) and in subjects who started treatment late (within 6 to 10 days after the onset of symptoms). The clinical analysis also showed that there was no death in the treatment group within 28 days, while there were 8 deaths in the placebo group. After completing the relevant submission, review and approval procedures, tengshengbo plans to work closely with the U.S. Food and drug administration to further promote the follow-up registration of this combination therapy p> < p > at present, the State Food and Drug Administration and the Department of health of Hong Kong, China have approved the application for new drug clinical trial of this combination therapy. Tengshengbo has also carried out further research in China and is evaluating the therapeutic effectiveness of lower dose combination therapy in phase 2 research P>
it is understood that BRII-196 and BRII-198 are Tengsheng drugs and the third people's Hospital of Tsinghua University and Shenzhen Municipal People's Hospital, from the rehabilitation period of COVID-19 pneumonia patients to obtain the non competitive new severe acute respiratory syndrome virus 2 monoclonal antibody, and the application of genetic engineering technology to reduce risk and obtain more lasting therapeutic effect. p> < p > small molecule oral drugs complete patient administration < / P > < p > recently, Kaifa Pharmaceutical Co., Ltd. disclosed that its phase III global multicenter clinical trial of prochloramide in the treatment of hospitalized Xinguan patients has completed the enrollment and administration of the first patient in a clinical center in the United States p> < p > prochloramide is the only small molecule oral drug that has entered the phase III registered clinical trial in the world for the treatment of severe patients with new crown. This study is a randomized, double-blind, placebo-controlled, global multicenter phase III clinical trial to explore the efficacy and safety of prochloramide in the treatment of hospitalized patients with new crowns. It is planned to recruit more than 1000 patients p> < p > Tong Youzhi, founder, chairman and CEO of pioneer pharmaceutical, said that the global multicenter clinical trial plan was carried out in hundreds of medical centers in 14 countries and has been approved in the United States, China, the Philippines, Brazil and other countries Novel coronavirus pneumonia can reduce novel coronavirus pneumonia and reduce the immune response and tissue damage in vivo. It suggests that it has a potential therapeutic mechanism for severe new crown pneumonia, which makes p>
a promising drug for the treatment of patients with mild, moderate and severe new crown pneumonia. In addition, p>
said that it has reached a cooperation with Wang Shan Shui Biological Medicine Co., Ltd., and will jointly undertake the clinical development and industrialization of the oral nucleoside anti COVID-19 candidate VV116 in the world. p> < p > vv116 was jointly developed by Shanghai Institute of pharmacy, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, Xinjiang Institute of physical and chemical technology, Chinese Academy of Sciences, Wangshan wangshui biomedical Co., Ltd. and Central Asia drug R & D center, Chinese Academy of Sciences, and submitted clinical trial applications to the drug regulatory authorities of China and Uzbekistan respectively, The application for clinical trial in Uzbekistan has been approved P>
preclinical pharmacodynamic studies show that VV116 has significant anti COVID-19 effects both in vivo and in vitro. Vv116 is a hydrobromide form of triisobutyrate prodrug. Preclinical pharmacokinetic results show that it has high oral bioavailability. After oral absorption, it is rapidly metabolized into maternal nucleoside, which can be widely distributed in vivo P>
, China's first anti COVID-19 neutralizing antibody, China, has received emergency use authorization in 15 overseas countries and regions, contributing to the global COVID-19 prevention and control. The real world will also push VV116 into clinical trials as soon as possible. P>
's innovative neutralizing antibody has been approved by
in China. The green leaf Pharmaceutical Group has announced significant progress in its innovative neutralizing antibody LY-CovMab for COVID-19 pneumonia, which has been independently developed by Boan bio. Preliminary validation shows that LY-CovMab can inhibit the infection of COVID-19, Alpha, Delta, Gamma, Lambda and other strains, and is expected to become a powerful weapon to cope with the new crown variation strain. At present, ly covmab has been approved to carry out phase II clinical trials in China p>
Ly covmab is a recombinant human monoclonal neutralizing antibody, which specifically binds to the spike protein receptor domain on the surface of coronavirus 2 with high affinity and strength, and can block the binding between the virus and the receptor angiotensin converting enzyme 2 on the surface of host cells, so as to prevent the virus from entering human cells p> < p > at present, the drug has planned to carry out phase II clinical trials in China and many countries around the world. Thanks to the special FC sequence design, ly covmab can avoid ade effect (antibody dependent enhancement). Based on potential therapeutic and preventive effects in various studies, LY-CovMab has been incorporated into New Coronavirus's neutralizing antibody product R & D emergency project. p> < p > Dou Changlin, President and chief operating officer of Boan biological research and development, said that he was promoting the international multicenter clinical research of ly covmab to help fight the "epidemic" in the world p> < p > source: Beijing daily client reporter Zhao Peng < / P > < p >